PCM
IRWD icon

Prelude Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Prelude Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-112,475
Closed -$1.41M – 1612
2017
Q4 		$1.41M Buy
+112,475
New +$1.47M 0.11% 186

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Prelude Capital Management's IRWD Position: Q1 2026 in Review

Prelude Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2026, closing a stake of 136,507 shares — an estimated $460K sold.

Prelude Capital Management first reported a position in IRWD in Q3 2016 and held it in 15 quarters. The position peaked at $1.65M in Q2 2021. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Prelude Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 136,507 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $460K.
  • Prelude Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2016 and held it in 15 quarters.
  • Prelude Capital Management's Ironwood Pharmaceuticals position peaked at $1.65M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.